A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M

Inclusion Criteria: Only participants who meet all the inclusion criteria will be enrolled into the trial: * Healthy infant aged 5-36 months at the time of first study vaccination * Parent/guardian provides signed/thumb-printed informed consent * Infant and parent/guardian resident in the study area villages and anticipated to be available for vaccination and the duration of follow-up Exclusion Criteria: The participant may not enter the trial if ANY of the following apply: * Clinically significant congenital abnormalities as judged by the PI or other delegated individual. * Clinically significant skin disorder (psoriasis, contact dermatitis etc.), cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness as judged by the PI or other delegated individual. * Weight-for-age Z score of less than -3 or other clinical signs of malnutrition. * History of allergic reaction, significant IgE-mediated event, or anaphylaxis to immunisation. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccines. * Sickle cell disease. * Clinically significant laboratory abnormality at grade 2 or above as judged by the PI or other delegated individual. * Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate. * Receipt of any vaccine in the 14 days preceding enrolment, or planned rece…